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ABSTRACT
duodenum = 2.5 6 0.67; P < 0.001) in CD, but not controls (TI = 2.11 6
0.41 versus duodenum = 2.26 6 0.61; P = 0.52). CYP3A4 expression
was decreased in CD (TI = –0.89 6 3.11 versus duodenum = 1.90 6
2.29; P < 0.05), but not controls (TI = 2.46 6 0.51 versus duodenum =
2.60 6 0.60; P = 0.61), as was VIL1 (CD TI = 3.80 6 0.94 versus
duodenum = 4.61 6 0.52; P < 0.001; controls TI = 4.30 6 0.35 versus
duodenum = 4.47 6 0.40; P = 0.29). PXR expression correlated with
VIL1 (r = 0.78, P = 0.01) and CYP3A4 (r = 0.52, P = 0.01) expression. In
conclusion, PXR, CYP3A4, and VIL1 expression was decreased only
in the actively inflamed small intestinal tissue in children with CD.
Our findings suggest that inflammation has the potential to influence
expression of genes, and potentially intestinal proteins, important to
drug disposition and response. The observed differential patterns of
gene expression support further investigation of the role of PXR in
the pathogenesis and/or treatment of pediatric Crohn’s disease.

Introduction

alterations in the intestinal epithelial barrier and microbiome (Sartor,
2006). A plausible mechanism linking xenobiotic exposure, inflammation, and immune (dys)function was recently explored in
animal models of IBD, where evidence from the mouse model
suggested a protective, anti-inflammatory effect of PXR activation in
the GI tract (Shah et al., 2007; Ma et al., 2007; Cheng et al., 2010).
The proposed mechanism involves PXR activation leading to
suppression of nuclear factor kB, a key component of the inflammatory cascade and a known regulator of the immune response
(Zhou et al., 2006). In children, the interpretation of such gene
expression studies may be confounded by ontogeny. Our aim was to
test the hypothesis that PXR and its target genes (e.g., CYP3A4) are
underexpressed in the actively inflamed small intestinal tissue of
children with Crohn’s disease, a type of IBD.

Human pregnane X receptor (PXR), a known transcriptional regulator
of important drug-metabolizing enzymes [e.g., cytochrome p450 3A4
(CYP3A4)] and transporters (e.g., ABCB1), is a ligand-activated nuclear
receptor expressed in the gastrointestinal (GI) tract, where it functions as
a xenobiotic sensor (Zhang et al., 2008). It is well established that
constant exposure to xenobiotics is not only capable of producing
inflammation and injury (Zhou et al., 2006; Zhang et al., 2008) but can
also impair immune function (Xie and Tian, 2006), raising the
possibility that inappropriate adaptive responses to xenobiotics may
contribute to the pathogenesis of immune-mediated inflammatory
pathologies, including inflammatory bowel disease (IBD).
IBD is a chronic inflammatory condition of the GI epithelial
mucosa that often manifests in childhood, with children comprising
20–25% of the total patient population (Leung et al., 2011). IBD is
thought to have its origins in an incompletely understood, multifactorial, disease-causing combination of genetic predisposition, aberrant immune response, environmental triggers, and pathologic
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Materials and Methods
These research activities were approved and declared nonhuman-subjects
research by the Institutional Review Board of the Children’s Mercy Hospital.
Tissue Specimens. Archived biopsy tissue samples from the duodenum and
terminal ileum (TI) were obtained from patients, 7–17 years old, with Crohn’s
disease (CD, n = 18) and age- and sex-matched non-IBD patients (control, n = 12)
who had normal-appearing duodenum and TI on esophagogastroduodenoscopy/
colonoscopy performed as part of routine care. Diagnosis of Crohn’s disease was
confirmed by clinical, radiographic, and histopathologic findings. All histopathology slides were independently reviewed by a single, experienced, boardcertified pediatric pathologist to ensure presence of inflammation in CD TI, but

ABBREVIATIONS: CD, Crohn’s disease; CYP3A4, cytochrome p450 3A4; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GI,
gastrointestinal; IBD, inflammatory bowel disease; PXR, pregnane X receptor; TI, terminal ileum; VIL1, villin 1.
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Expression of the pregnane X receptor (PXR) has been reported to
be decreased in animal models of inflammatory bowel disease (IBD).
To investigate the differential expression of PXR in children with
Crohn’s disease, a type of IBD, RNA was extracted from archived
intestinal biopsies from 18 children with Crohn’s disease (CD) and 12
age- and sex-matched controls (aged 7–17yrs). The aim of this
investigation was to compare the relative mRNA expression of PXR,
cytochrome p450 3A4 (CYP3A4), and villin 1 (VIL1) (a marker of
epithelial cell integrity) in the inflamed terminal ileum (TI) versus
noninflamed duodenum of children with CD. Relative expression
was determined via reverse transcription real-time quantitative
polymerase chain reaction, data normalized to glyceraldehyde 3phosphate dehydrogenase, and differences in gene expression
explored via paired t tests. PXR expression was decreased in the
inflamed TI versus noninflamed duodenum (TI = 1.88 6 0.89 versus

PXR Expression in Pediatric Crohn’s
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not CD duodenum or any control tissues. Presence/absence of inflammation was
additionally verified by IL8 and iNOS gene expression studies performed on all
biopsy samples.
RNA Extraction and Quantitative Reverse Transcription–Real-Time
Quantitative Polymerase Chain Reaction. Total RNA was prepared from four
10-mm sections of archived formalin-fixed paraffin-embedded intestinal biopsy
samples using the RNeasy formalin-fixed paraffin-embedded RNA Isolation Kit
(Qiagen, Valencia, CA), according to manufacturer’s protocol, including oncolumn DNase I treatment. RNA quantity was determined on a Nanodrop ND1000 Spectrophotometer. Total RNA (200 ng) was reverse transcribed using the
High-Capacity RNA-to-cDNA Kit (Applied Biosystems/Thermo Fisher Scientific). RNA quality was estimated by performing glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) 39:59 assays (Nolan et al., 2006). RNA integrity is
inferred from the ratio of quantities of the two PCR products targeting the 39 and
59 ends of GAPDH mRNA, which reflects successful reverse transcription across
GAPDH. Ratios closest to one are indicative of good quality RNA.
Primers for the 39 GAPDH assay were 59 AGTCCCTGCCACACTCAG
(forward) and 59 TACTTTATTGATGGTACATGACAAGG (reverse); 59
GTGAACCATGAGAAGTATGACAAC (forward) and 59 CATGAGTCCTTCCACGATACC (reverse) for the 59 GAPDH assay. GAPDH assays were
performed with 2 ml cDNA, 250 nM each forward and reverse primers, and
PerfeCta SYBR green SuperMix (Quanta Biosciences, Gaithersburg, MD). Gene
expression assays for PXR (Hs00243666_m1), VIL1 (Hs00200229_m1), CYP3A4
(Hs00604506_m1), IL8 (Hs99999034_m1), and NOS2 (Hs01075529_m1) were
performed using 2 ml cDNA, TaqMan Gene Expression Assay (Applied
Biosystems), and PerfeCTa qPCR SuperMix (Quanta Biosciences). Standard
curves were generated using serial dilutions of cDNA plasmids from 10 to 108
copies/ml. Molecule numbers were determined from linear regression of the
standard curves. All gene expression assays were performed with triplicate
determinations of molecule numbers for each sample. When sample replicates
varied more than 0.5 Ct, the assay was repeated in triplicate.
Data Analysis. Only tissue samples of adequate quality mRNA (i.e., GAPDH
39:59 ratios less than 10) were included in the study analysis. For relative mRNA
expression quantification, replicate determinations of molecule numbers were
averaged, normalized to the mean of GAPDH molecule numbers, and logarithmically transformed, as data were not normally distributed. Differences in
normalized, log2-transformed, unit-less, relative gene expression were compared
between the TI and the duodenum, using a two-tailed paired Student’s t test.
Spearman’s correlation and linear regression analyses were carried out to explore
relevant associations. All analyses were conducted using SAS version 9.2 (SAS
Institute Inc., Cary, NC) and SPSS version 20 (IBM) with a significance limit set
at a = 0.05.

Results and Discussion
mRNA expression patterns of PXR, CYP3A4, and VIL1 observed in
our pediatric patient cohorts are presented in Fig. 1. GAPDH expression
did not differ with age, sex, or location along the small intestine in the CD
or the control cohort (data not shown). In children with CD, PXR
expression was decreased in inflamed TI versus noninflamed duodenum
(TI = 1.88 6 0.89 versus duodenum = 2.5 6 0.67; P , 0.001), but not in
controls (TI = 2.11 6 0.41 versus duodenum = 2.26 6 0.61; P = 0.52).
Likewise, expression of CYP3A4 was decreased in inflamed TI of
children with CD (TI = –0.89 6 3.11 versus duodenum = 1.90 6 2.29;
P = 0.014), but not in controls (TI = 2.46 6 0.51 versus duodenum = 2.60 6
0.60; P = 0.61). VIL1 expression [indicator of epithelial cell integrity
(Simms et al., 2008)] was also decreased in inflamed TI of children with
CD (TI = 3.80 6 0.94 versus duodenum = 4.61 6 0.52; P , 0.001), but
not in controls (TI = 4.30 6 0.35 versus duodenum = 4.47 6 0.40; P =
0.29). A positive correlation between PXR and CYP3A4 expression
(Supplemental Fig. 1) was observed (r = 0.517, P = 0.01), as expected,
given that CYP3A is a known target of PXR (Timsit and Negishi, 2007).
Correlation relationships for all genes of interest, across all samples, are
summarized in the supplemental documents (Supplemental Table 1).
Unexpectedly, a significant correlation between PXR and VIL1 expression was observed across all samples (r = 0.780, P = 0.01; Fig. 2A), as

Fig. 1. Relative gene expression of PXR (A), VIL1 (B), and CYP3A4 (C) in the TI
and the duodenum of children with Crohn’s disease (CD; n = 18) versus age- and
sex-matched controls without IBD (n = 12). Mean differences in relative gene
expression (triplicate determinations of molecule number per sample, normalized
to GAPDH, and log2-transformed) were compared between the TI and the
duodenum in the same children, using a two-tailed paired Student’s t test (a =
0.05).
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well as between CYP3A4 and VIL1 (Supplemental Fig. 2). Expression of
PXR (Fig. 2B), VIL1 (Fig. 2C), and CYP3A4 (Fig. 2D) correlated
inversely with IL8 (marker of inflammation) in the TI of CD, but not
controls. The observed trend in inverse correlation between IL8 and the
genes of interest reached statistical significance for CYP3A4 (P , 0.01)
and approached significance for PXR (P = 0.06) and VIL1 (P = 0.07) in
the inflamed TI of CD (Supplemental Table 2). This inverse correlation
was not observed in noninflamed tissues (e.g., control TI).
Our study results demonstrate a significant decrease in PXR expression
only in the inflamed small intestinal tissue (i.e., TI) in children with CD,
relative to uninflamed small intestinal tissue from the same children
(i.e., duodenum); Fig. 1A. The strength of our study resides in utilization
of noninflamed duodenal tissue from each subject as a negative control
for that subject, effectively eliminating interindividual genetic variability
as a confounding factor in our mRNA analysis. As no difference in PXR
expression was observed between the TI and the duodenum in age- and
sex-matched controls, the observed decrease in PXR in the CD TI cannot
be attributed to biopsy site location along the small intestinal tract. More
probably, the observed decrease represents the effect of inflammation or
disease on the intestinal epithelium, and the diverse population of
enzymes, proteins, and receptors that reside within it. Taken together, our
observations of the differential patterns of expression in PXR, CYP3A4,
and VIL1 in children with CD raise several important implications.

First, expression of all genes of interest was lower in CD versus
controls, implying that disease/inflammation per se have the potential to
produce a significant effect on the expression of genes important to drug
disposition and response, including drug-metabolizing enzymes (e.g.,
CYP3A4) and presumably transporters (e.g., ABCB1). In the case of
CYP3A4, the observed disease-associated finding could potentially
impact intestinal drug biotransformation, and the rate/extent of bioavailability, of perorally administered drugs. This disease effect could be
quite dynamic in a given pediatric patient, as the extent of inflammation
changes between the time of disease onset/flare and disease remission
and mucosal repair. Given apparent age-related differences in biotransformation of certain CYP3A4 substrates (e.g., cyclosporine,
tacrolimus, midazolam) (Kearns et al., 2003), ontogeny could also be an
important covariate; although, we did not detect any age-related changes
over the investigated age range (7–17yrs).
Second, our observation of decreased PXR expression in actively
inflamed versus noninflamed tissue in patients with CD suggests that
PXR may play a role in the disease phenotype expression of CD,
accounting for the pathognomonic skip lesions characteristic of the
disease. Potential mechanisms to support the role of PXR in CD
pathogenesis can be inferred from animal studies that demonstrate a
mutual and reciprocal repression between PXR and NF-kB (Ma et al.,
2007; Shah et al., 2007; Zhou et al., 2006). Alternatively, given the
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Fig. 2. Correlation relationships (Spearman’s correlation; a = 0.05) in relative gene expression (triplicate determinations of molecule number per sample, normalized to
GAPDH, and log2-transformed) between (A) PXR and VIL1 across all tissue samples (n = 30; r = 0.78, P = 0.01); (B) PXR and IL8 in the TI of CD (r = –0.45, P = 0.06) and
controls (r = 0.18, P = 0.6), (C) VIL1 and IL8 in the TI of CD (r = –0.44, P = 0.07) and controls (r = 0.27, P = 0.4), and (D) CYP3A4 and IL8 in the TI of CD (r = –0.68, P ,
0.01) and controls (r = 0.21, P = 0.5). Crohn’s disease (CD) tissue denoted by cross (n = 18), control tissue by circle (n = 12).
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recent implication of PXR activation in epithelial cell repair mechanisms
via the p38 mitogen-activated protein kinase–dependent pathway in
mice (Terc et al., 2014), our observed decrease in PXR (Fig. 1A) may be
related to impaired epithelial barrier integrity thought to contribute to the
development of IBD. This is supported by our observation of decreased
VIL1 expression (marker of epithelial integrity) in the inflamed CD TI
(Fig. 1B).
Although our mRNA data would be strengthened by protein studies,
such studies could not be performed, as archived biopsy tissues of
limited quantity were used and depleted during the gene experiments
described above. A prospective study utilizing fresh biopsy tissue
samples from children is underway to address this study limitation.
Herein, we provide preliminary evidence concerning a complex
interplay between intestinal inflammation in pediatric patients with
Crohn’s disease and the expression of PXR, VIL1, and CYP3A4 in the GI
tract. Prospective studies will differentiate whether our observations
have a structural (e.g., tissue damage/loss) or a mechanistic (e.g., disease
modification) basis. In the meantime, our data raise the question of what
happens to PXR, its target genes, epithelial cell repair mechanisms, and
mucosal healing when PXR is exogenously activated by ligands. Adult
studies exploring the utility of PXR agonists (e.g., rifaximin) in the
treatment of IBD are ongoing (Prantera et al., 2012). Further exploration
of PXR’s potential as a novel/adjunct therapeutic target in pediatric
Crohn’s disease is warranted.
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